Mirum Pharmaceuticals (MIRM) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Mirum Pharmaceuticals, Inc. (MIRM) reported $148.93 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 49.8%. EPS of -$0.11 for the same period compares to -$0.49 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $141.27 million, representing a surprise of +5.42%. The company delivered an EPS surprise of -650%, with the consensus EPS estimate being $0.02.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Mirum Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Total product sales, net: $148.93 million compared to the $142.62 million average estimate based on four analysts.
• Product Sales- Bile Acid Medicines: $42.55 million compared to the $42.58 million average estimate based on three analysts.
• Product Sales- Livmarli: $106.39 million versus $98.37 million estimated by three analysts on average.

View all Key Company Metrics for Mirum Pharmaceuticals here>>>

Shares of Mirum Pharmaceuticals have returned +8.3% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Mirum Pharmaceuticals, Inc. (MIRM): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research